{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:08:05Z","timestamp":1793725685354,"version":"4.6.1"},"reference-count":191,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is the most recently defined inflammatory demyelinating disease of the central nervous system (CNS). Over the last decade, several studies have helped delineate the characteristic clinical-MRI phenotypes of the disease, allowing distinction from aquaporin-4 (AQP4)-IgG-positive neuromyelitis optica spectrum disorder (AQP4-IgG+NMOSD) and multiple sclerosis (MS). The clinical manifestations of MOGAD are heterogeneous, ranging from isolated optic neuritis or myelitis to multifocal CNS demyelination often in the form of acute disseminated encephalomyelitis (ADEM), or cortical encephalitis. A relapsing course is observed in approximately 50% of patients. Characteristic MRI features have been described that increase the diagnostic suspicion (e.g., perineural optic nerve enhancement, spinal cord H-sign, T2-lesion resolution over time) and help discriminate from MS and AQP4+NMOSD, despite some overlap. The detection of MOG-IgG in the serum (and sometimes CSF) confirms the diagnosis in patients with compatible clinical-MRI phenotypes, but false positive results are occasionally encountered, especially with indiscriminate testing of large unselected populations. The type of cell-based assay used to evaluate for MOG-IgG (fixed vs. live) and antibody end-titer (low vs. high) can influence the likelihood of MOGAD diagnosis. International consensus diagnostic criteria for MOGAD are currently being compiled and will assist in clinical diagnosis and be useful for enrolment in clinical trials. Although randomized controlled trials are lacking, MOGAD acute attacks appear to be very responsive to high dose steroids and plasma exchange may be considered in refractory cases. Attack-prevention treatments also lack class-I data and empiric maintenance treatment is generally reserved for relapsing cases or patients with severe residual disability after the presenting attack. A variety of empiric steroid-sparing immunosuppressants can be considered and may be efficacious based on retrospective or prospective observational studies but prospective randomized placebo-controlled trials are needed to better guide treatment. In summary, this article will review our rapidly evolving understanding of MOGAD diagnosis and management.<\/jats:p>","DOI":"10.3389\/fneur.2022.885218","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T02:55:04Z","timestamp":1655434504000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":320,"title":["Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management"],"prefix":"10.3389","volume":"13","author":[{"given":"Elia","family":"Sechi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cacciaguerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mariotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Fadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Dinoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Sebastian","family":"Lopez-Chiriboga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean J.","family":"Pittock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoin P.","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nm1488","article-title":"Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein","volume":"13","author":"O'Connor","year":"2007","journal-title":"Nat Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat Rev Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1212\/CON.0000000000000742","article-title":"Neuromyelitis optica spectrum disorder and other non-multiple sclerosis central nervous system inflammatory diseases","volume":"25","author":"Flanagan","year":"2019","journal-title":"Continuum (Minneap Minn)."},{"key":"B5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1742-2094-10-8","article-title":"The history of neuromyelitis optica","volume":"10","author":"Jarius","year":"2013","journal-title":"J Neuroinflammation."},{"key":"B6","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/archneur.63.7.964","article-title":"Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression","volume":"63","author":"Pittock","year":"2006","journal-title":"Arch Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1177\/1352458517721661","article-title":"Late presentation of NMOSD as rapidly progressive leukoencephalopathy with atypical clinical and radiological findings","volume":"24","author":"Sechi","year":"2018","journal-title":"Mult Scler."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1212\/WNL.0b013e318214332c","article-title":"Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications","volume":"76","author":"Popescu","year":"2011","journal-title":"Neurology."},{"key":"B10","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology."},{"key":"B12","first-page":"423","article-title":"The M2 autoantigen of central nervous system myelin, a glycoprotein present in oligodendrocyte membrane","volume":"66","author":"Lebar","year":"1986","journal-title":"Clin Exp Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1056\/NEJMoa022328","article-title":"Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event","volume":"349","author":"Berger","year":"2003","journal-title":"N Engl J Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1056\/NEJMoa063602","article-title":"Lack of association between antimyelin antibodies and progression to multiple sclerosis","volume":"356","author":"Kuhle","year":"2007","journal-title":"N Engl J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1212\/01.WNL.0000127615.15768.AE","article-title":"Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects","volume":"62","author":"Lampasona","year":"2004","journal-title":"Neurology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1177\/1352458510376406","article-title":"Serum antibodies to conformational and linear epitopes of myelin oligodendrocyte glycoprotein are not elevated in the preclinical phase of multiple sclerosis","volume":"16","author":"Chan","year":"2010","journal-title":"Mult Scler."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1177\/1352458514566666","article-title":"Anti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohort","volume":"21","author":"Ketelslegers","year":"2015","journal-title":"Mult Scler."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1212\/NXI.0000000000000163","article-title":"Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS","volume":"2","author":"Kim","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B19","doi-asserted-by":"publisher","first-page":"20552173211052656","DOI":"10.1177\/20552173211052656","article-title":"Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders","volume":"7","author":"Redenbaugh","year":"2021","journal-title":"Mult Scler J Exp Transl Clin."},{"key":"B20","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"102742","DOI":"10.1016\/j.msard.2021.102742","article-title":"What percentage of AQP4-ab-negative NMOSD patients are MOG-ab positive? A study from the Argentinean multiple sclerosis registry (RelevarEM)","volume":"49","author":"Carnero Contentti","year":"2021","journal-title":"Mult Scler Relat Disord."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders","volume":"75","author":"Lopez-Chiriboga","year":"2018","journal-title":"JAMA Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1001\/jamaneurol.2020.2743","article-title":"Application of 2015 seronegative neuromyelitis optica spectrum disorder diagnostic criteria for patients with myelin oligodendrocyte glycoprotein IgG-associated disorders","volume":"77","author":"Kunchok","year":"2020","journal-title":"JAMA Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S1474-4422(20)30432-4","article-title":"Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care","volume":"20","author":"Fadda","year":"2021","journal-title":"Lancet Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","article-title":"The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody","volume":"139","author":"Hoftberger","year":"2020","journal-title":"Acta Neuropathol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/acn3.164","article-title":"Histopathology and clinical course of MOG-antibody-associated encephalomyelitis","volume":"2","author":"Spadaro","year":"2015","journal-title":"Ann Clin Transl Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1093\/brain\/awaa102","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study","volume":"143","author":"Takai","year":"2020","journal-title":"Brain."},{"key":"B30","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes","volume":"77","author":"Waters","year":"2020","journal-title":"JAMA Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1177\/1352458515622986","article-title":"Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case","volume":"22","author":"Jarius","year":"2016","journal-title":"Mult Scler."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1212\/NXI.0000000000000175","article-title":"Fulminant demyelinating encephalomyelitis: Insights from antibody studies and neuropathology","volume":"2","author":"Di Pauli","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B33","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/ana.26226","article-title":"Complement Activation Is a Prominent Feature of MOGAD","volume":"90","author":"Keller","year":"2021","journal-title":"Ann Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jneuroim.2017.01.007","article-title":"MOG-antibody associated demyelinating disease of the CNS: A clinical and pathological study in Chinese Han patients","volume":"305","author":"Zhou","year":"2017","journal-title":"J Neuroimmunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00415-019-09586-5","article-title":"MOG-IgG-associated demyelination: focus on atypical features, brain histopathology and concomitant autoimmunity","volume":"267","author":"Papathanasiou","year":"2020","journal-title":"J Neurol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3389\/fneur.2020.00031","article-title":"A fulminant case of demyelinating encephalitis with extensive cortical involvement associated with anti-MOG antibodies","volume":"11","author":"Hochmeister","year":"2020","journal-title":"Front Neurol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00401-021-02286-3","article-title":"Antibodies to MOG in CSF only: pathological findings support the diagnostic value","volume":"141","author":"Carta","year":"2021","journal-title":"Acta Neuropathol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e335","DOI":"10.1212\/NXI.0000000000000335","article-title":"ADEM-like presentation, anti-MOG antibodies, and MS pathology: TWO case reports","volume":"4","author":"Kortvelyessy","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B39","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/ana.26279","article-title":"Investigating the Immunopathogenic Mechanisms Underlying MOGAD","volume":"91","author":"McCombe","year":"2022","journal-title":"Ann Neurol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"577699","DOI":"10.1016\/j.jneuroim.2021.577699","article-title":"C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD","volume":"360","author":"Pache","year":"2021","journal-title":"J Neuroimmunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/ana.24617","article-title":"Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum","volume":"79","author":"Flanagan","year":"2016","journal-title":"Ann Neurol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1471-2377-13-128","article-title":"Incidence and prevalence of multiple sclerosis in Europe: a systematic review","volume":"13","author":"Kingwell","year":"2013","journal-title":"BMC Neurol."},{"key":"B43","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide incidence and prevalence of neuromyelitis optica: a systematic review","volume":"96","author":"Papp","year":"2021","journal-title":"Neurology."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e858","DOI":"10.1212\/NXI.0000000000000713","article-title":"High incidence and prevalence of MS in More and Romsdal County, Norway, 1950-2018","volume":"7","author":"Willumsen","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B45","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1001\/jamaneurol.2019.3656","article-title":"Coexistence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibodies in adult and pediatric patients","volume":"77","author":"Kunchok","year":"2020","journal-title":"JAMA Neurol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1136\/jnnp-2018-320243","article-title":"Seroprevalence and clinical phenotype of MOG-IgG-associated disorders in Sri Lanka","volume":"90","author":"Senanayake","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B47","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.msard.2018.07.026","article-title":"Lower frequency of antibodies to MOG in Brazilian patients with demyelinating diseases: an ethnicity influence?","volume":"25","author":"Papais-Alvarenga","year":"2018","journal-title":"Mult Scler Relat Disord."},{"key":"B48","doi-asserted-by":"publisher","first-page":"100021","DOI":"10.1016\/j.lanwpc.2020.100021","article-title":"Incidence of neuromyelitis optica spectrum disorder (NMOSD) in China: a national population-based study","volume":"2","author":"Tian","year":"2020","journal-title":"Lancet Reg Health West Pac."},{"key":"B49","doi-asserted-by":"publisher","first-page":"100010","DOI":"10.1016\/j.lanwpc.2020.100010","article-title":"Incidence of multiple sclerosis in China: a nationwide hospital-based study","volume":"1","author":"Tian","year":"2020","journal-title":"Lancet Reg Health West Pac."},{"key":"B50","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ajo.2020.07.014","article-title":"Population-based incidence of optic neuritis in the era of aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies","volume":"220","author":"Hassan","year":"2020","journal-title":"Am J Ophthalmol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e414","DOI":"10.1212\/WNL.0000000000007828","article-title":"Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology","volume":"93","author":"Sechi","year":"2019","journal-title":"Neurology."},{"key":"B52","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/ana.25909","article-title":"Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"89","author":"Cobo-Calvo","year":"2021","journal-title":"Ann Neurol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1001\/jamaneurol.2018.4053","article-title":"Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody","volume":"76","author":"Dubey","year":"2019","journal-title":"JAMA Neurol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/brain\/aww350","article-title":"Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e1097","DOI":"10.1212\/WNL.0000000000012467","article-title":"Comparison of MRI lesion evolution in different central nervous system demyelinating disorders","volume":"97","author":"Sechi","year":"2021","journal-title":"Neurology."},{"key":"B56","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1136\/jnnp-2014-310206","article-title":"MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study","volume":"87","author":"Akaishi","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B57","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am J Ophthalmol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1474-4422(19)30488-0","article-title":"Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study","volume":"19","author":"Armangue","year":"2020","journal-title":"Lancet Neurol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/1352458520907900","article-title":"Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies","volume":"27","author":"Sechi","year":"2021","journal-title":"Mult Scler."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e2128871","DOI":"10.1001\/jamanetworkopen.2021.28871","article-title":"Comparison of spinal cord magnetic resonance imaging features among children with acquired demyelinating syndromes","volume":"4","author":"Fadda","year":"2021","journal-title":"JAMA Netw Open."},{"key":"B61","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/ana.25411","article-title":"Brain and cord imaging features in neuromyelitis optica spectrum disorders","volume":"85","author":"Cacciaguerra","year":"2019","journal-title":"Ann Neurol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1093\/brain\/awz144","article-title":"Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines","volume":"142","author":"Filippi","year":"2019","journal-title":"Brain."},{"key":"B63","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain."},{"key":"B64","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s12974-018-1335-x","article-title":"Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies","volume":"15","author":"Lee","year":"2018","journal-title":"J Neuroinflammation."},{"key":"B65","doi-asserted-by":"publisher","first-page":"101965","DOI":"10.1016\/j.msard.2020.101965","article-title":"Prodromal headache in MOG-antibody positive optic neuritis","volume":"40","author":"Asseyer","year":"2020","journal-title":"Mult Scler Relat Disord."},{"key":"B66","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1177\/13524585211011450","article-title":"Optic chiasm involvement in AQP-4 antibody-positive NMO and MOG antibody-associated disorder","volume":"28","author":"Tajfirouz","year":"2021","journal-title":"Mult Scler"},{"key":"B67","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/ene.15178","article-title":"Chiasmatic lesions on conventional magnetic resonance imaging during the first event of optic neuritis in patients with neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein-associated disease in a Latin American cohort","volume":"29","author":"Carnero Contentti","year":"2021","journal-title":"Eur J Neurol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12883-017-0971-6","article-title":"MOG antibody seropositivity in a patient with encephalitis: beyond the classical syndrome","volume":"17","author":"Mariotto","year":"2017","journal-title":"BMC Neurol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"e1351","DOI":"10.1212\/WNL.0000000000012599","article-title":"CNS demyelinating attacks requiring ventilatory support with myelin oligodendrocyte glycoprotein or aquaporin-4 antibodies","volume":"97","author":"Zhao-Fleming","year":"2021","journal-title":"Neurology."},{"key":"B70","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/dmcn.13649","article-title":"'Leukodystrophy-like' phenotype in children with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"60","author":"Hacohen","year":"2018","journal-title":"Dev Med Child Neurol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1212\/WNL.0000000000010662","article-title":"Bilateral extensive corticospinal tract lesions in MOG antibody-associated disease","volume":"95","author":"Mastrangelo","year":"2020","journal-title":"Neurology."},{"key":"B72","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/ana.25146","article-title":"Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies","volume":"83","author":"Maggi","year":"2018","journal-title":"Ann Neurol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/13524585211007086","article-title":"Central vein sign and other radiographic features distinguishing myelin oligodendrocyte glycoprotein antibody disease from multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica","volume":"28","author":"Ciotti","year":"2022","journal-title":"Mult Scler."},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-325121","article-title":"Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS","author":"Banks","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B75","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1212\/WNL.0000000000008786","article-title":"Does area postrema syndrome occur in myelin oligodendrocyte glycoprotein-IgG-associated disorders (MOGAD)?","volume":"94","author":"Kunchok","year":"2020","journal-title":"Neurology."},{"key":"B76","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1007\/s00415-017-8635-4","article-title":"Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study","volume":"264","author":"Mariotto","year":"2017","journal-title":"J Neurol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"101487","DOI":"10.1016\/j.msard.2019.101487","article-title":"The frequency of longitudinally extensive transverse myelitis in MS: a population-based study","volume":"37","author":"Asnafi","year":"2020","journal-title":"Mult Scler Relat Disord."},{"key":"B78","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1055\/s-0041-1733792","article-title":"Evaluation and Management of acute myelopathy","volume":"41","author":"Sechi","year":"2021","journal-title":"Semin Neurol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"e601","DOI":"10.1212\/CPJ.0000000000001036","article-title":"Utility of MRI Enhancement Pattern in Myelopathies With Longitudinally Extensive T2 Lesions","volume":"11","author":"Mustafa","year":"2021","journal-title":"Neurol Clin Pract."},{"key":"B80","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1212\/WNL.0000000000002992","article-title":"Central canal enhancement and the trident sign in spinal cord sarcoidosis","volume":"87","author":"Zalewski","year":"2016","journal-title":"Neurology."},{"key":"B81","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1136\/jnnp-2016-314738","article-title":"Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders","volume":"88","author":"Zalewski","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1007\/s00415-019-09440-8","article-title":"Unilateral cortical FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis with Seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome","volume":"266","author":"Budhram","year":"2019","journal-title":"J Neurol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1212\/NXI.0000000000000322","article-title":"MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy","volume":"4","author":"Ogawa","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B84","doi-asserted-by":"publisher","first-page":"775181","DOI":"10.3389\/fneur.2021.775181","article-title":"Case report: four cases of cortical\/brainstem encephalitis positive for myelin oligodendrocyte glycoprotein immunoglobulin G","volume":"12","author":"Wang","year":"2021","journal-title":"Front Neurol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1001\/jamaneurol.2020.0001","article-title":"Unilateral Leptomeningeal Enhancement in Myelin Oligodendrocyte Glycoprotein Immunoglobulin G-Associated Disease","volume":"77","author":"Budhram","year":"2020","journal-title":"JAMA Neurol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1161\/STROKEAHA.116.016194","article-title":"Primary angiitis of the central nervous system: magnetic resonance imaging spectrum of parenchymal, meningeal, and vascular lesions at baseline","volume":"48","author":"Boulouis","year":"2017","journal-title":"Stroke."},{"key":"B87","doi-asserted-by":"publisher","first-page":"e924","DOI":"10.1212\/NXI.0000000000000924","article-title":"Overlapping central and peripheral nervous system syndromes in MOG antibody-associated disorders","volume":"8","author":"Rinaldi","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B88","doi-asserted-by":"publisher","first-page":"e503","DOI":"10.1212\/NXI.0000000000000503","article-title":"MOG. antibodies in combined central and peripheral demyelination syndromes","volume":"5","author":"Vazquez Do Campo","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B89","doi-asserted-by":"publisher","first-page":"e543","DOI":"10.1212\/NXI.0000000000000543","article-title":"Cranial nerve involvement in patients with MOG antibody-associated disease","volume":"6","author":"Cobo-Calvo","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B90","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1177\/1352458518811597","article-title":"Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis","volume":"25","author":"Oliveira","year":"2019","journal-title":"Mult Scler."},{"key":"B92","doi-asserted-by":"publisher","first-page":"103229","DOI":"10.1016\/j.msard.2021.103229","article-title":"Myelin oligodendrocyte glycoprotein (MOG) antibody-mediated disease: the difficulty of predicting relapses","volume":"56","author":"Epstein","year":"2021","journal-title":"Mult Scler Relat Disord."},{"key":"B93","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s00415-018-9160-9","article-title":"Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults","volume":"266","author":"Cobo-Calvo","year":"2019","journal-title":"J Neurol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1212\/WNL.0000000000004312","article-title":"Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome","volume":"89","author":"Hennes","year":"2017","journal-title":"Neurology."},{"key":"B95","doi-asserted-by":"publisher","first-page":"e2137833","DOI":"10.1001\/jamanetworkopen.2021.37833","article-title":"Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder","volume":"4","author":"Camera","year":"2021","journal-title":"JAMA Netw Open."},{"key":"B96","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/ana.25957","article-title":"Silent new brain MRI lesions in children with MOG-antibody associated disease","volume":"89","author":"Fadda","year":"2021","journal-title":"Ann Neurol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1093\/brain\/awaa347","article-title":"Quantitative spinal cord MRI in MOG-antibody disease, neuromyelitis optica and multiple sclerosis","volume":"144","author":"Mariano","year":"2021","journal-title":"Brain."},{"key":"B98","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1136\/jnnp-2020-324826","article-title":"Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS","volume":"92","author":"Duan","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B99","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1101\/2020.09.22.20198978","article-title":"Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis","volume":"28","author":"Messina","year":"2021","journal-title":"Mult Scler"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1001\/jamaneurol.2020.3115","article-title":"Long-term outcomes in patients with myelin oligodendrocyte glycoprotein immunoglobulin G-associated disorder","volume":"77","author":"Lopez-Chiriboga","year":"2020","journal-title":"JAMA Neurol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"117088","DOI":"10.1016\/j.jns.2020.117088","article-title":"Unfavorable outcome in highly relapsing MOGAD encephalitis","volume":"418","author":"Buciuc","year":"2020","journal-title":"J Neurol Sci."},{"key":"B102","doi-asserted-by":"publisher","first-page":"722404","DOI":"10.3389\/fimmu.2021.722404","article-title":"Clinical and imaging features of patients with encephalitic symptoms and myelin oligodendrocyte glycoprotein antibodies","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"e1912732","DOI":"10.1001\/jamanetworkopen.2019.12732","article-title":"Comparison of Clinical outcomes of transverse myelitis among adults with myelin oligodendrocyte glycoprotein antibody vs aquaporin-4 antibody disease","volume":"2","author":"Mariano","year":"2019","journal-title":"JAMA Netw Open."},{"key":"B104","doi-asserted-by":"publisher","first-page":"103689","DOI":"10.1016\/j.msard.2022.103689","article-title":"Cognitive function in pediatric-onset relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)","volume":"59","author":"Fabri","year":"2022","journal-title":"Mult Scler Relat Disord."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1111\/ene.14746","article-title":"The long-term outcome of MOGAD: An observational national cohort study of 61 patients","volume":"28","author":"Deschamps","year":"2021","journal-title":"Eur J Neurol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"103222","DOI":"10.1016\/j.msard.2021.103222","article-title":"Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease","volume":"56","author":"Akaishi","year":"2021","journal-title":"Mult Scler Relat Disord."},{"key":"B107","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s12974-020-01825-1","article-title":"Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients","volume":"17","author":"Jarius","year":"2020","journal-title":"J Neuroinflammation."},{"key":"B108","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12974-020-01824-2","article-title":"Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: results from 163 lumbar punctures in 100 adult patients","volume":"17","author":"Jarius","year":"2020","journal-title":"J Neuroinflammation."},{"key":"B109","doi-asserted-by":"publisher","first-page":"102638","DOI":"10.1016\/j.msard.2020.102638","article-title":"Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-IgG-associated disorder","volume":"47","author":"Sechi","year":"2021","journal-title":"Mult Scler Relat Disord."},{"key":"B110","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1136\/jnnp-2012-304695","article-title":"Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude","volume":"84","author":"Dobson","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B111","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1136\/jnnp-2018-317969","article-title":"CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications","volume":"89","author":"Kaneko","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B112","doi-asserted-by":"publisher","first-page":"2055217319848463","DOI":"10.1177\/2055217319848463","article-title":"Distinct serum and cerebrospinal fluid cytokine and chemokine profiles in autoantibody-associated demyelinating diseases","volume":"5","author":"Hofer","year":"2019","journal-title":"Mult Scler J Exp Transl Clin."},{"key":"B113","doi-asserted-by":"publisher","first-page":"647618","DOI":"10.3389\/fimmu.2021.647618","article-title":"Serum neurofilament light and GFAP are associated with disease severity in inflammatory disorders with aquaporin-4 or myelin oligodendrocyte glycoprotein antibodies","volume":"12","author":"Chang","year":"2021","journal-title":"Front Immunol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"e708","DOI":"10.1212\/NXI.0000000000000708","article-title":"Serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"7","author":"Kim","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1136\/jnnp-2018-320287","article-title":"Neurofilament light chain serum levels reflect disease severity in MOG-Ab associated disorders","volume":"90","author":"Mariotto","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B116","doi-asserted-by":"publisher","first-page":"116986","DOI":"10.1016\/j.jns.2020.116986","article-title":"Serum neurofilament light chain studies in neurological disorders, hints for interpretation","volume":"416","author":"Mariotto","year":"2020","journal-title":"J Neurol Sci."},{"key":"B117","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1161\/STROKEAHA.120.031482","article-title":"Serum neurofilament to magnetic resonance imaging lesion area ratio differentiates spinal cord infarction from acute myelitis","volume":"52","author":"Sechi","year":"2021","journal-title":"Stroke."},{"key":"B118","doi-asserted-by":"publisher","first-page":"102833","DOI":"10.1016\/j.msard.2021.102833","article-title":"NfL levels predominantly increase at disease onset in MOG-Abs-associated disorders","volume":"50","author":"Mariotto","year":"2021","journal-title":"Mult Scler Relat Disord."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1177\/1352458520951046","article-title":"MOG-IgG1 and co-existence of neuronal autoantibodies","volume":"27","author":"Kunchok","year":"2021","journal-title":"Mult Scler."},{"key":"B120","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/ana.24117","article-title":"Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis","volume":"75","author":"Titulaer","year":"2014","journal-title":"Ann Neurol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1177\/1352458520933884","article-title":"Coexisting systemic and organ-specific autoimmunity in MOG-IgG1-associated disorders versus AQP4-IgG+ NMOSD","volume":"27","author":"Kunchok","year":"2021","journal-title":"Mult Scler."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.mayocp.2018.02.006","article-title":"Frequency of aquaporin-4 immunoglobulin g in longitudinally extensive transverse myelitis with antiphospholipid antibodies","volume":"93","author":"Guerra","year":"2018","journal-title":"Mayo Clin Proc."},{"key":"B123","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s13311-019-00796-3","article-title":"Anti-Neuronal antibodies within the IVIg preparations: importance in clinical practice","volume":"17","author":"Dimitriadou","year":"2020","journal-title":"Neurotherapeutics."},{"key":"B124","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/cei.13641","article-title":"Clinical and neuroimaging findings in MOGAD-MRI and OCT","volume":"206","author":"Bartels","year":"2021","journal-title":"Clin Exp Immunol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"540156","DOI":"10.3389\/fneur.2020.540156","article-title":"AQP4-IgG and MOG-IgG related optic neuritis-prevalence, optical coherence tomography findings, and visual outcomes: a systematic review and meta-analysis","volume":"11","author":"Filippatou","year":"2020","journal-title":"Front Neurol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1177\/1352458520937281","article-title":"Visual field loss and structure-function relationships in optic neuritis associated with myelin oligodendrocyte glycoprotein antibody","volume":"27","author":"Deschamps","year":"2021","journal-title":"Mult Scler."},{"key":"B127","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12974-019-1521-5","article-title":"Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study","volume":"16","author":"Oertel","year":"2019","journal-title":"J Neuroinflammation."},{"key":"B128","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1177\/1756285616655264","article-title":"Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders","volume":"9","author":"Martinez-Lapiscina","year":"2016","journal-title":"Ther Adv Neurol Disord."},{"key":"B129","doi-asserted-by":"publisher","first-page":"103525","DOI":"10.1016\/j.msard.2022.103525","article-title":"OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis: RNFL thickening in acute optic neuritis from MOGAD vs MS","volume":"58","author":"Chen","year":"2022","journal-title":"Mult Scler Relat Disord."},{"key":"B130","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1136\/jnnp-2014-309704","article-title":"The temporal evolution of structural and functional measures after acute optic neuritis","volume":"86","author":"Costello","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B131","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/ana.20851","article-title":"Quantifying axonal loss after optic neuritis with optical coherence tomography","volume":"59","author":"Costello","year":"2006","journal-title":"Ann Neurol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.msard.2018.04.006","article-title":"Frequent retinal ganglion cell damage after acute optic neuritis","volume":"22","author":"Brandt","year":"2018","journal-title":"Mult Scler Relat Disord."},{"key":"B133","doi-asserted-by":"publisher","first-page":"20552173211066446","DOI":"10.1177\/20552173211066446","article-title":"The use of OCT in good visual acuity MOGAD and AQP4-NMOSD patients; with and without optic neuritis","volume":"7","author":"Roca-Fernandez","year":"2021","journal-title":"Mult Scler J Exp Transl Clin."},{"key":"B134","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.msard.2018.11.026","article-title":"Unique characteristics of optical coherence tomography (OCT) results and visual acuity testing in myelin oligodendrocyte glycoprotein (MOG) antibody positive pediatric patients","volume":"28","author":"Narayan","year":"2019","journal-title":"Mult Scler Relat Disord."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1177\/1352458519864928","article-title":"Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning","volume":"26","author":"Sotirchos","year":"2020","journal-title":"Mult Scler."},{"key":"B136","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J Neuroinflammation."},{"key":"B137","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1001\/jamaneurol.2021.0912","article-title":"Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing","volume":"78","author":"Sechi","year":"2021","journal-title":"JAMA Neurol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"e674","DOI":"10.1212\/NXI.0000000000000674","article-title":"International multicenter examination of MOG antibody assays","volume":"7","author":"Reindl","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B139","doi-asserted-by":"publisher","first-page":"e1250","DOI":"10.1212\/WNL.0000000000007096","article-title":"A multicenter comparison of MOG-IgG cell-based assays","volume":"92","author":"Waters","year":"2019","journal-title":"Neurology."},{"key":"B140","doi-asserted-by":"publisher","first-page":"e1867","DOI":"10.1212\/WNL.0000000000008479","article-title":"Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases","volume":"93","author":"Mariotto","year":"2019","journal-title":"Neurology."},{"key":"B141","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1212\/WNL.0000000000012175","article-title":"Difference in the source of anti-AQP4-IgG and Anti-MOG-IgG antibodies in CSF in patients with neuromyelitis optica spectrum disorder","volume":"97","author":"Akaishi","year":"2021","journal-title":"Neurology."},{"key":"B142","doi-asserted-by":"publisher","first-page":"e1095","DOI":"10.1212\/NXI.0000000000001095","article-title":"Myelin oligodendrocyte glycoprotein-immunoglobulin G in the CSF: clinical implication of testing and association with disability","volume":"28","author":"Kwon","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B143","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1136\/jnnp-2021-326779","article-title":"Frequency of MOG-IgG in cerebrospinal fluid versus serum","volume":"93","author":"Pace","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B144","doi-asserted-by":"publisher","first-page":"673339","DOI":"10.3389\/fneur.2021.673339","article-title":"Antibody-Mediated Autoimmune Diseases of the CNS: challenges and approaches to diagnosis and management","volume":"12","author":"Sechi","year":"2021","journal-title":"Front Neurol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"20552173211022767","DOI":"10.1177\/20552173211022767","article-title":"Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients","volume":"7","author":"Held","year":"2021","journal-title":"Mult Scler J Exp Transl Clin."},{"key":"B146","doi-asserted-by":"publisher","first-page":"20552173211048761","DOI":"10.1177\/20552173211048761","article-title":"Clinical significance of myelin oligodendrocyte glycoprotein autoantibodies in patients with typical MS lesions on MRI","volume":"7","author":"Zara","year":"2021","journal-title":"Mult Scler J Exp Transl Clin."},{"key":"B147","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s10072-020-04942-0","article-title":"Clinical features and management of coexisting anti-N-methyl-D-aspartate receptor encephalitis and myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis: a case report and review of the literature","volume":"42","author":"Nan","year":"2021","journal-title":"Neurol Sci."},{"key":"B148","doi-asserted-by":"publisher","first-page":"e2442","DOI":"10.1212\/WNL.0000000000010632","article-title":"Neurologic autoimmunity and immune checkpoint inhibitors: autoantibody profiles and outcomes","volume":"95","author":"Sechi","year":"2020","journal-title":"Neurology."},{"key":"B149","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jtho.2020.11.005","article-title":"Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies","volume":"16","author":"Sechi","year":"2021","journal-title":"J Thorac Oncol."},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211057512","article-title":"MOG-antibody-associated longitudinal extensive myelitis after ChAdOx1 nCoV-19 vaccination","author":"Dams","year":"2021","journal-title":"Mult Scler"},{"key":"B151","doi-asserted-by":"publisher","first-page":"577739","DOI":"10.1016\/j.jneuroim.2021.577739","article-title":"Longitudinally extensive transverse myelitis with anti-myelin oligodendrocyte glycoprotein antibodies following SARS-CoV-2 infection","volume":"361","author":"Dias da Costa","year":"2021","journal-title":"J Neuroimmunol."},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103424","article-title":"Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD","author":"Dinoto AS","year":"2022","journal-title":"Mult Scler Relat Disord."},{"key":"B153","doi-asserted-by":"publisher","first-page":"103189","DOI":"10.1016\/j.msard.2021.103189","article-title":"Patient-reported safety and tolerability of the COVID-19 vaccines in persons with rare neuroimmunological diseases","volume":"55","author":"Lotan","year":"2021","journal-title":"Mult Scler Relat Disord."},{"key":"B154","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1001\/jamaneurol.2020.1162","article-title":"Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events","volume":"77","author":"Kunchok","year":"2020","journal-title":"JAMA Neurol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"120044","DOI":"10.1016\/j.jns.2021.120044","article-title":"Exposure to TNF inhibitors is rare at MOGAD presentation","volume":"432","author":"Redenbaugh","year":"2022","journal-title":"J Neurol Sci."},{"key":"B156","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1212\/NXI.0000000000000497","article-title":"Posttransplant autoimmune encephalitis","volume":"5","author":"Cohen","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B157","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1212\/WNL.0000000000010310","article-title":"GABAA receptor autoimmunity after alemtuzumab treatment for multiple sclerosis","volume":"95","author":"Maniscalco","year":"2020","journal-title":"Neurology."},{"key":"B158","doi-asserted-by":"publisher","first-page":"e2006","DOI":"10.1212\/WNL.0000000000011744","article-title":"Pregnancy in Patients With AQP4-Ab, MOG-Ab, or Double-Negative Neuromyelitis Optica Disorder","volume":"96","author":"Collongues","year":"2021","journal-title":"Neurology."},{"key":"B159","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation."},{"key":"B160","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00401-020-02236-5","article-title":"MOG-expressing teratoma followed by MOG-IgG-positive optic neuritis","volume":"141","author":"Wildemann","year":"2021","journal-title":"Acta Neuropathol."},{"key":"B161","doi-asserted-by":"publisher","first-page":"e572","DOI":"10.1212\/NXI.0000000000000572","article-title":"Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?","volume":"6","author":"Stiebel-Kalish","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B162","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::aid-ana10>3.0.co;2-q","article-title":"A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease","volume":"46","author":"Weinshenker","year":"1999","journal-title":"Ann Neurol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.autrev.2006.08.011","article-title":"Safety of intravenous immunoglobulin (IVIG) therapy","volume":"6","author":"Katz","year":"2007","journal-title":"Autoimmun Rev."},{"key":"B164","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1001\/archneur.1982.00510180028007","article-title":"Complications of plasma exchange in neurological patients","volume":"39","author":"Rodnitzky","year":"1982","journal-title":"Arch Neurol."},{"key":"B165","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/art.1780300413","article-title":"Infective complications of plasma exchange: a prospective study","volume":"30","author":"Singer","year":"1987","journal-title":"Arthritis Rheum."},{"key":"B166","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1212\/WNL.0000000000009758","article-title":"Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder","volume":"95","author":"Chen","year":"2020","journal-title":"Neurology."},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.0489","article-title":"Association of maintenance intravenous immunoglobulin with prevention of relapse in adult myelin oligodendrocyte glycoprotein antibody-associated disease","author":"Chen","year":"2022","journal-title":"JAMA Neurol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"103462","DOI":"10.1016\/j.msard.2021.103462","article-title":"Treatment of myelin oligodendrocyte glycoprotein antibody associated disease with subcutaneous immune globulin","volume":"57","author":"Sotirchos","year":"2021","journal-title":"Mult Scler Relat Disord."},{"key":"B169","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/ana.25648","article-title":"Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases","volume":"87","author":"Durozard","year":"2020","journal-title":"Ann Neurol."},{"key":"B170","doi-asserted-by":"publisher","first-page":"102251","DOI":"10.1016\/j.msard.2020.102251","article-title":"Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients","volume":"44","author":"Whittam","year":"2020","journal-title":"Mult Scler Relat Disord."},{"key":"B171","doi-asserted-by":"publisher","first-page":"e463","DOI":"10.1212\/NXI.0000000000000463","article-title":"Monitoring B-cell repopulation after depletion therapy in neurologic patients","volume":"5","author":"Ellwardt","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B172","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40120-018-0101-4","article-title":"Only follow-up of memory b cells helps monitor rituximab administration to patients with neuromyelitis optica spectrum disorders","volume":"7","author":"Lebrun","year":"2018","journal-title":"Neurol Ther."},{"key":"B173","doi-asserted-by":"publisher","first-page":"577666","DOI":"10.1016\/j.jneuroim.2021.577666","article-title":"Prolonged B-cell depletion after rituximab in AQP4-IgG-positive neuromyelitis optica spectrum disorder","volume":"358","author":"Sechi","year":"2021","journal-title":"J Neuroimmunol."},{"key":"B174","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol."},{"key":"B175","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1002\/acn3.51136","article-title":"Serious safety events in rituximab-treated multiple sclerosis and related disorders","volume":"7","author":"Vollmer","year":"2020","journal-title":"Ann Clin Transl Neurol."},{"key":"B176","doi-asserted-by":"publisher","first-page":"13524585211049737","DOI":"10.1177\/13524585211049737","article-title":"Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica","author":"Januel","year":"2021","journal-title":"Mult Scler"},{"key":"B177","doi-asserted-by":"publisher","first-page":"e1057","DOI":"10.1212\/NXI.0000000000001057","article-title":"COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America: From the COViMS Registry","volume":"8","author":"Newsome","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B178","doi-asserted-by":"publisher","first-page":"103554","DOI":"10.1016\/j.msard.2022.103554","article-title":"Humoral and cellular immune responses to SARS CoV-2 vaccination in People with Multiple Sclerosis and NMOSD patients receiving immunomodulatory treatments","volume":"59","author":"Bock","year":"2022","journal-title":"Mult Scler Relat Disord."},{"key":"B179","doi-asserted-by":"publisher","first-page":"103035","DOI":"10.1016\/j.msard.2021.103035","article-title":"Differential efficacy of mycophenolate mofetil in adults with relapsing myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"53","author":"Wang","year":"2021","journal-title":"Mult Scler Relat Disord."},{"key":"B180","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1007\/s00415-020-10026-y","article-title":"Treatment of MOG antibody associated disorders: results of an international survey","volume":"267","author":"Whittam","year":"2020","journal-title":"J Neurol."},{"key":"B181","doi-asserted-by":"publisher","first-page":"102696","DOI":"10.1016\/j.msard.2020.102696","article-title":"Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): a case-series and review","volume":"48","author":"Elsbernd","year":"2021","journal-title":"Mult Scler Relat Disord."},{"key":"B182","doi-asserted-by":"publisher","first-page":"e1100","DOI":"10.1212\/NXI.0000000000001100","article-title":"Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders","volume":"9","author":"Ringelstein","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B183","doi-asserted-by":"publisher","first-page":"e919","DOI":"10.1212\/NXI.0000000000000919","article-title":"Targeting B cells to modify MS, NMOSD, and MOGAD: part 2","volume":"8","author":"Graf","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B184","doi-asserted-by":"publisher","first-page":"e918","DOI":"10.1212\/NXI.0000000000000918","article-title":"Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1","volume":"8","author":"Graf","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B185","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet."},{"key":"B186","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med."},{"key":"B187","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard JF","year":"2021","journal-title":"Lancet Neurol."},{"key":"B188","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1111\/ene.14729","article-title":"Pain, depression, and quality of life in adults with MOG-antibody-associated disease","volume":"28","author":"Asseyer","year":"2021","journal-title":"Eur J Neurol."},{"key":"B189","doi-asserted-by":"publisher","first-page":"e985","DOI":"10.1212\/NXI.0000000000000985","article-title":"Pain, Depression, and quality of life in neuromyelitis optica spectrum disorder: a cross-sectional study of 166 AQP4 antibody-seropositive patients","volume":"8","author":"Ayzenberg","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B190","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1001\/archneurol.2012.112","article-title":"Painful tonic spasm in neuromyelitis optica: incidence, diagnostic utility, and clinical characteristics","volume":"69","author":"Kim","year":"2012","journal-title":"Arch Neurol."},{"key":"B191","doi-asserted-by":"publisher","first-page":"17562864211054157","DOI":"10.1177\/17562864211054157","article-title":"Efficacy and safety of immunosuppressive therapy in myelin oligodendrocyte glycoprotein antibody-associated disease: a systematic review and meta-analysis","volume":"14","author":"Lai","year":"2021","journal-title":"Ther Adv Neurol Disord."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.885218\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T23:05:53Z","timestamp":1727391953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.885218\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":191,"alternative-id":["10.3389\/fneur.2022.885218"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.885218","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"article-number":"885218"}}